Intervention not reported
ASCVD event, such as fatal or non‐fatal myocardial infarction or stroke. Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
The intervention showed no clear difference in ASCVD event, such as fatal or non‐fatal myocardial infarction or… (low certainty).
1 finding from 1 review
Intervention not reported
Any investigator‐defined adverse event Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
The intervention probably leads to higher any investigator‐defined adverse event Median (moderate certainty).
1 finding from 1 review
Intervention not reported
Systolic blood pressure, mmHg Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
1 finding from 1 review
Intervention not reported
Total cholesterol, mmol/L Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
1 finding from 1 review
Intervention not reported
LDL cholesterol, mmol/L Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
1 finding from 1 review
Intervention not reported
Adherence, variable definitions Median · adults older than 18 years, with no restriction regarding presence of ASCVD; participants generally had elevated risk of ASCVD (as…
The intervention probably leads to higher adherence, variable definitions Median (moderate certainty).
1 finding from 1 review
Outcomes · people with confirmed diagnosis of Marfan syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in all‐cause mortality compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Clinically important non‐fatal end point as defined byShores 1994(aortic dissection, aortic regurgitation, congestive heart failure, or cardiovascular surgery) · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in clinically important non‐fatal end point as defined byShores… compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Acute aortic dissection · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in acute aortic dissection compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Aortic regurgitation · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in aortic regurgitation compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Congestive heart failure · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in congestive heart failure compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Cardiovascular surgery · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in cardiovascular surgery compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Aortic root diameter > 6 cm · people with confirmed diagnosis of Marfan syndrome
Beta‐blockers showed no clear difference in aortic root diameter > 6 cm compared with placebo, no treatment or surveillance only (low certainty).
1 finding from 1 review
Major cardiovascular event Physicians · middle‐aged US male physicians
Vitamin C supplementation showed no clear difference in major cardiovascular event Physicians compared with placebo (low certainty).
1 finding from 1 review
Cardiovascular mortality Physicians · middle‐aged US male physicians
It is very uncertain whether vitamin C supplementation changes cardiovascular mortality Physicians compared with placebo (very low certainty).
1 finding from 1 review
All‐cause mortality Physicians · middle‐aged US male physicians
It is very uncertain whether vitamin C supplementation changes all‐cause mortality Physicians compared with placebo (very low certainty).
1 finding from 1 review
Fatal or nonfatal myocardial infarction · middle‐aged US male physicians
Vitamin C supplementation showed no clear difference in total myocardial infarction (fatal and non‐fatal) Physicians compared with placebo (low certainty).
1 finding from 1 review
Stroke · middle‐aged US male physicians
Vitamin C supplementation showed no clear difference in total stroke (fatal and non‐fatal) Physicians compared with placebo (low certainty).
1 finding from 1 review
Self‐reported CABG/PTCA Participant self‐reports · middle‐aged US male physicians
Vitamin C supplementation showed no clear difference in self‐reported CABG/PTCA Participant self‐reports compared with placebo (low certainty).
1 finding from 1 review